Systematic Analysis of Targets of Pumilio-Mediated mRNA Decay Reveals that PUM1 Repression by DNA Damage Activates Translesion Synthesis.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
05 05 2020
Historique:
received: 11 07 2019
revised: 28 01 2020
accepted: 31 03 2020
entrez: 7 5 2020
pubmed: 7 5 2020
medline: 4 6 2021
Statut: ppublish

Résumé

RNA-binding proteins (RBPs) play a pivotal role in gene expression by modulating the stability of transcripts. However, the identification of degradation target mRNAs of RBPs remains difficult. By the combined analysis of transcriptome-wide mRNA stabilities and the binding of mRNAs to human Pumilio 1 (PUM1), we identify 48 mRNAs that both bind to PUM1 and exhibit PUM1-dependent degradation. Analysis of changes in the abundance of PUM1 and its degradation target mRNAs in RNA-seq data indicate that DNA-damaging agents negatively regulate PUM1-mediated mRNA decay. Cells exposed to cisplatin have reduced PUM1 abundance and increased PCNA and UBE2A mRNAs encoding proteins involved in DNA damage tolerance by translesion synthesis (TLS). Cells overexpressing PUM1 exhibit impaired DNA synthesis and TLS and increased sensitivity to the cytotoxic effect of cisplatin. Thus, our method identifies target mRNAs of PUM1-mediated decay and reveals that cells respond to DNA damage by inhibiting PUM1-mediated mRNA decay to activate TLS.

Identifiants

pubmed: 32375027
pii: S2211-1247(20)30442-3
doi: 10.1016/j.celrep.2020.107542
pii:
doi:

Substances chimiques

PUM1 protein, human 0
RNA, Messenger 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107542

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

Toshimichi Yamada (T)

Meiji Pharmaceutical University, Kiyose-shi, Tokyo 204-8588, Japan.

Naoto Imamachi (N)

Isotope Science Center, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.

Katsutoshi Imamura (K)

Isotope Science Center, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.

Kenzui Taniue (K)

Isotope Science Center, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.

Takeshi Kawamura (T)

Isotope Science Center, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.

Yutaka Suzuki (Y)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa-shi, Chiba 277-8562, Japan.

Masami Nagahama (M)

Meiji Pharmaceutical University, Kiyose-shi, Tokyo 204-8588, Japan.

Nobuyoshi Akimitsu (N)

Isotope Science Center, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan. Electronic address: akimitsu@ric.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH